PROS1 and prostate carcinoma: The focus of Tosoian et al.’s study was on the use of the MyProstateScore 2.0 (MPS2) diagnostic test, which combines traditional PSA testing with the analysis of genes specific to aggressive prostate cancer, aimed at improving the diagnostic accuracy of prostate cancer and reducing the excessive number of biopsies.